Notably, the diabetes therapeutic metformin (Met) effectively disrupts these Twist1-YY1-p300 condensates, leading to significant downregulation of miR-9 expression and subsequent suppression of HCC malignancy (Meng et al., 2023). The gene discussed is TWIST1; the disease is hepatocellular carcinoma.